

## **Press Release**

Stockholm, 27 March 2009

### **Notice of Annual General Meeting of Biovitrum AB, 28 April 2009**

In accordance with the listing agreement with NASDAQ OMX Stockholm AB, Biovitrum AB (publ) hereby announces, also by issuing a press release, the content of the notice concerning Biovitrum's Annual General Meeting on 28 April 2009, and the complete proposal from the Board of Directors regarding the performance based, long-term share program for 2009 comprising proposal regarding a directed issue of series C shares and proposal regarding authorization for the board of directors to repurchase issued series C shares.

Attachments:

- Notice of Biovitrum's Annual General Meeting 2009
- Proposal from the Board of Directors regarding the performance based, long-term share program for 2009 comprising proposal regarding a directed issue of series C shares and proposal regarding authorization for the board of directors to repurchase issued series C shares

#### **For further information please contact:**

Martin Nicklasson, CEO

Phone: +46 8 697 25 45

Göran Arvidson, CFO

Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations

Cell phone: +46 73 422 15 40

[erik.kinnman@biovitrum.com](mailto:erik.kinnman@biovitrum.com)

#### **About Biovitrum**

Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.1 billion and around 400 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to [www.biovitrum.com](http://www.biovitrum.com).